A randomized, double-blind
, placebo-controlled study.
Do editors employing a single-blind review process systematically publish more papers that have little or no impact on the profession and/or fail to publish more truly good papers than do editors of double-blind
Throughout the double-blind
treatment period, which was the first eight weeks of the study, patients treated with LUNESTA plus fluoxetine showed improvements in time to sleep onset (p en 0.
All 45 MPS I patients from the six-month, randomized, double-blind
, placebo-controlled Phase 3 trial were enrolled in the open-label extension study in order to further evaluate the safety and efficacy of Aldurazyme.
Dynogen currently has multiple double-blind
, placebo-controlled Phase 2 studies underway.
As previously announced, T2000 is currently being studied for the treatment of moderate to severe essential tremor in a multi-center, randomized, double-blind
, placebo-controlled trial in Canada.
05) improvements from baseline in sleep onset, TST, WASO and number of awakenings, during each double-blind
assessment week and when averaged over the 8-week, double-blind
Nasdaq: SEPR) today announced the publication of results from its Phase IIIB/IV, 410-patient, randomized, double-blind
, placebo-controlled study evaluating the safety and efficacy of LUNESTA([R]) brand eszopiclone for the treatment of insomnia in perimenopausal and menopausal women suffering from insomnia.
Nasdaq:DYAX) announced today that it has completed the double-blind
portion of its pivotal Phase III clinical trial, known as EDEMA3, for its lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE).
Jenny Starosta will conduct a double-blind
placebo-controlled study designed and supervised by renowned alcoholism researcher, Dr.
This Phase 2, double-blind
, randomized, placebo-controlled, parallel group trial compared two doses of denufosol tetrasodium inhalation solution to placebo over 28 days of dosing in 13 CF patients, five to seven years of age.
The first study (Part A) was a double-blind
and placebo-controlled 6-week trial, in which patients randomized to receive IL-1 Trap had an approximately 85% reduction in their mean symptom score compared to an approximately 13% reduction in patients treated with placebo (p<0.